Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stablix Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and a distinct art unit. The concentration of the pending office action under a distinct examiner suggests a focused prosecution path for the company's current intellectual property efforts. This arrangement means that the company's immediate results in this technology area are dependent on the review of the assigned examiner. Practitioners should note that with a distinct examiner and a distinct art unit involved, there is no internal baseline for comparing examiner behavior or art unit trends within this specific portfolio.
The busiest examiner for the portfolio is ARCORIA, PAUL JOSEPH, who is currently responsible for the busiest examiner pending office action. This specific examiner's handling of the 1 pending office action indicates that the company's current activity is not spread across different personnel. Because the portfolio is limited to a distinct art unit, the technical focus remains narrow. The pending office action represents the entirety of the company's current pending workload in this specific technology area, which may simplify the management of the prosecution timeline for the applicant.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18752702 | AKT INHIBITORS | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18752702 | AKT INHIBITORS | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Jun 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStablix Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Joseph Arcoria has the most, with 1 of Stablix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.